Video

Emerging treatment options for variant histology bladder cancer

Fed Ghali, MD, a urologic oncology fellow at the University of Washington, discusses the outlook for patients with variant histology bladder cancer and how antibody-drug conjugates may provide a new treatment option in this setting. Ghali presented the abstract, “Antibody-drug conjugates and variant histology muscle-invasive bladder cancer: are the targets present in primary and/or metastatic tumors?” at the 2022 AUA Annual Meeting (abstract PD53-09).

Related Videos
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
© 2025 MJH Life Sciences

All rights reserved.